Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc

<< Previous

Bullboard Posts

Next >>

Post by TheBearInTheWoodson Aug 13, 2021 11:19am

131 Views

Post# 33700643

Phase II Clinical Data going for third party review

Phase II Clinical Data going for third party review

"Arch Biopartners Inc. has provided an update that the analysis of the results of the phase II trial of its lead drug LSALT peptide (metablok) is continuing and will be disclosed to the public following third party, scientific peer review."

ARCH.V - 56% held by insiders

Canadian Innovation Funded Phase II humna trial on Organ inflammation

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project